Navigation Links
PrimeraDx Appoints Jeff Liter as VP of Corporate Development

MANSFIELD, Mass., Oct. 13, 2011 /PRNewswire/ -- PrimeraDx today announced that Jeff Liter has been appointed as the Vice President of Corporate Development.  

"Jeff's diverse background in all aspects of corporate development makes him a great addition to the leadership team," Said Matt McManus, President and CEO, PrimeraDx.  "PrimeraDx's strategy is to leverage the multimodal capabilities of the ICEPlex system in the MDx market and define a model for the next generation of molecular diagnostics.  Jeff has a great deal of experience that will help bring scale to our commercial efforts."

Mr. Liter has more than 20 years of experience in business development, sales, corporate finance and operations.  Prior to joining PrimeraDx, he was the Director of Strategy, Business Development, & Licensing for Beckman Coulter, where he was responsible for Business Development of the Immunoassay and Molecular Diagnostics Groups.  Jeff also was the managing director with On Point Consulting, focusing on Post Acquisition Integration Support and Transactional Advisory Services.  Specifically, he delivered integration services to Onyx Pharmaceuticals and established a Knowledge Transfer Program within the first 3 months of a critical integration.  He received his MBA from University of Minnesota and his BA from Illinois State University.

"The ICEPlex platform is already creating a stir in the MDx community, with the ability to assay mRNAs, microRNAs and SNPs in the same well, from a single sample," Commented Mr. Liter.  "I am excited to work with Matt and the team, to develop the company's customer base and strategic alliances."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: or

CONTACT: Andrew Bond, +1-508-618-2752,

SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
2. PrimeraDx Appoints Albert A. Luderer to its Board of Directors
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Omeros Appoints David A. Mann to its Board of Directors
5. RainDance Technologies Appoints Olex Vice President, System Development
6. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
7. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
8. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
9. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
10. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
11. UltraShape Appoints Assaf Eyal as President & CEO
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon ... over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... a wide range of applications such as, but not limited to, biotechnology, biomedical, ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):